Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors(LiFFT) | recruiting | Phase 1 / Phase 2 | 63 | Children's Hospital of PhiladelphiaOTHER |
| 1 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT05939180 | VA vs DA for Newly Diagnosed Hig-risk AML | recruiting | Phase 2 / Phase 3 | 116 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06043817 | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | recruiting | Phase 1 / Phase 2 | 345 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06284590 | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients(INTACT/MeRCI) | recruiting | Phase 2 | 162 | Philogen S.p.A.INDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 2, 2026 | clinicaltrials |
| NCT06567015 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs(STX-241 FIH) | recruiting | Phase 1 / Phase 2 | 171 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial(PREDICT) | recruiting | Phase 2 | 474 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06728410 | A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | recruiting | Phase 2 | 38 | Mehmet AkceOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06795412 | Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 220 | Pyxis Oncology, IncINDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT07025824 | Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation(RELEVANT) | recruiting | Phase 2 | 220 | Technische Universität DresdenOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07138755 | The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients | recruiting | Phase 2 | 35 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07252739 | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | recruiting | Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 2, 2026 | clinicaltrials |
| NCT07292298 | Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates | recruiting | Phase 2 | 44 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07293247 | A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment | recruiting | Phase 2 | 164 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07328425 | Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS(ISG-TULIPS) | recruiting | Phase 2 | 20 | Italian Sarcoma GroupNETWORK | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07354074 | Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP | recruiting | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 13 | Sep 2, 2026 | clinicaltrials |
| NCT07463248 | PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy | recruiting | Phase 2 | 64 | Wang XinOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07622186 | A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 150 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07648030 | A Study of Rusfertide in Japanese Adults With Polycythemia Vera | recruiting | Phase 2 | 9 | TakedaINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04546399 | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | recruiting | Phase 2 | 461 | National Cancer Institute (NCI)NIH | 4 | Sep 1, 2026 | clinicaltrials |
| NCT05304481 | Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma | recruiting | Phase 2 | 95 | Lukas Biomedical Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05322850 | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | recruiting | Phase 1 / Phase 2 | 40 | University of FloridaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement(FOENIX-CCA4) | recruiting | Phase 2 | 120 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 1, 2026 | clinicaltrials |
| NCT05958121 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Immatics Biotechnologies GmbHINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | recruiting | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06561347 | Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM(ZEBRA) | recruiting | Phase 2 | 65 | Massachusetts General HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06898970 | Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma | recruiting | Phase 2 | 18 | Varun Monga, MBBSOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06992258 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer(FRUITION) | recruiting | Phase 2 | 120 | Criterium, Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07029737 | A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain(SOUND-MCL) | recruiting | Phase 2 | 55 | AstraZenecaINDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07232602 | KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) | recruiting | Phase 1 / Phase 2 | 55 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 1, 2026 | clinicaltrials |
| NCT07294664 | PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer | recruiting | Phase 2 | 78 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07371234 | Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Rui YouOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07428993 | Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma | recruiting | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07432022 | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07486817 | Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab | recruiting | Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07700160 | First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | VelaVigo Bio IncINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer(OC) | recruiting | Phase 1 / Phase 2 | 72 | Tubulis GmbHINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07797816 | Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer | recruiting | Phase 2 | 31 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02133196 | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05272826 | Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients(BOREALIS) | recruiting | Phase 2 | 75 | Canadian Myeloma Research GroupOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05726292 | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | recruiting | Phase 2 | 90 | University of ChicagoOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05830058 | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | recruiting | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Sep 2, 2026source: clinicaltrials